However, 92% of responders in this cohort where MHC class I negative, suggesting that the efficacy of PD-1 blockade in relapsed/refractory (R/R) cHL does not depend on CD8+ T-cell mediated cytotoxicity [180]. The gene discussed is CD8A; the disease is classic Hodgkin lymphoma.